POR Recombinant Monoclonal Antibody

說(shuō)明書

中文名稱：

POR Recombinant Monoclonal Antibody
貨號(hào)：

CSB-RA976601A0HU
規(guī)格：

￥1320
圖片：
IHC image of CSB-RA976601A0HU diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.

IHC image of CSB-RA976601A0HU diluted at 1:100 and staining in paraffin-embedded human liver tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of HepG2 cell with CSB-RA976601A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Overlay Peak curve showing HepG2 cells stained with CSB-RA976601A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for?10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P16435
基因名：

POR
別名：

NADPH--cytochrome P450 reductase (CPR) (P450R) (EC 1.6.2.4), POR, CYPOR
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide from human POR protein
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

5G4
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, IF, FC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow cytometry (FC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
基因功能參考文獻(xiàn)：
1. Both CYP1A2 and CYP2B4 activities were affected by their coexpression in a manner consistent with formation of the high-affinity POR-CYP1A2-CYP2B4 complex. PMID: 29233819
2. genetic association studies in population in Scotland: data suggest, in type 2 diabetes treated with sulfonylureas, 2 SNPs in CYP2C9 (CYP2C9*2, R144C, rs1799853; CYP2C9*3, I359L, rs1057910) are associated with drug-induced hypoglycemia; an SNP in POR (POR*28, A503V, rs1057868) is associated with better response to sulfonylureas. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; POR = cytochrome p450 oxidoreductase) PMID: 28656666
3. The POR*28 heterozygote appears to be associated with the stable dose of acenocoumarol. PMID: 28592191
4. Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher cyclosporine dosing requirements and lower concentration/dose ratio. PMID: 29135906
5. Suggest that hepatic POR and P450s are coregulated, and that POR plays a complex role in P450-mediated metabolism. PMID: 27271371
6. A homodimer model can resolve the conundrum as to how cytochrome P450 oxidoreductase and cytochrome b5 compete for the same binding site on cytochrome P450c17. (Review) PMID: 28000554
7. Compound heterozygosity of a paternal submicroscopic deletion and a maternal missense mutation in POR gene: Antley-bixler syndrome phenotype in three sibling fetuses PMID: 26969897
8. analysis of mutations and polymorphisms in POR linked to metabolism of steroids and xenobiotics and pathology of P450 oxidoreductase deficiency (PORD) PMID: 27068427
9. No significant differences in the distribution of haplotypes between cases and controls were detected. In conclusion, this study reveals that four SNPs in the POR gene (rs3823884, rs3898649, rs239953 and rs17685) may affect the susceptibility of smoking cessation in a Chinese Han population. PMID: 27660057
10. analysis of the role of the active site loop in coenzyme binding and flavin reduction in cytochrome P450 reductase PMID: 27461959
11. Current studies demonstrate that, unlike previously described mutations, A287P causes POR deficiency disorder due to conformational instability leading to proteolytic susceptibility in vivo, rather than through an inherent flavin-binding defect. PMID: 27496950
12. population pharmacokinetic analysis identified that the combined genotype of CYP3A5-POR was the only covariant for the apparent clearance of tacrolimus PMID: 26227094
13. Case Report: delayed diagnosis of 46, XY disorder of sex development due to P450 oxidoreductase (POR) deficiency. PMID: 27376429
14. Interindividual variability in CYP2C19 activity is due to differences in both CYP2C19 protein content associated with gene diplotypes and the cytochrome P450 oxidoreductase content. PMID: 26323597
15. POR rs2868177 and CYP2B6*6 variants contribute to the interindividual variability in human CYP2B6 activity, which may affect the disposition and interaction of other CYP2B6 substrate drugs PMID: 27439448
16. For the first time, the SNP POR*37 831-35C>T was confirmed as a minor but statistically significant factor associated with inter-individual variation in warfarin maintenance dose in Han Chinese PMID: 27488389
17. POR*28 does not significantly influence Tac pharmacokinetic parameters. PMID: 26829596
18. the POR g.6593A>G polymorphism significantly influences CYP2B6 activity PMID: 26580670
19. P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects PMID: 26669712
20. POR A503V might decrease the risk of bladder cancer by reducing its metabolic activity. PMID: 26123203
21. POR besides CYP2B6 can influence cyclophosphamide metabolism PMID: 26544874
22. Study is a thorough structural, dynamic, and thermodynamic characterization of the soluble form of human microsomal CPR using small-angle x-ray scattering and nuclear magnetic resonance spectroscopy under various conditions PMID: 25809265
23. This study confirmed that CYP3A5*1 was associated with lower tacrolimus trough concentrations. POR*28 was associated with decreased tacrolimus trough concentrations although the effect was small possibly through enhanced CYP3A4 enzyme activity. PMID: 26067485
24. electron transfer between mCPR and aromatase PMID: 26087061
25. POR is the main determinant of SN30000 sensitivity in 3 different genetic backgrounds. Head and neck squamous cell carcinomas showed heterogeneous POR expression. There may be a relationship between HPV status and hypoxia-activated prodrug sensitivity. PMID: 26297733
26. We identified seven unreported SNP genetic variations. The p.Pro384Leu variant exhibited reduced enzymatic activities compared with wild-type. PMID: 25712184
27. Results show that combining the CYP3A5*1, POR*28 and CYP3A4*22 genotypes allows partial differentiation of early tacrolimus dose requirements and the time to reach therapeutic target concentrations after transplantation. PMID: 25322286
28. In children with FH, carriage of POR*28 allele is associated with reduced effect of atorvastatin on TChol and LDLc and therefore identifies FH children that may require higher atorvastatin doses to achieve full therapeutic benefits PMID: 25521355
29. Transient kinetic dissection of the reaction of POR with NADPH and the reduction in cytochrome c by POR using stopped-flow techniques revealed defects in individual electron transfer steps mediated by A287P. PMID: 25728647
30. Interactions of HO-2 with CPR and BVR, were evaluated. PMID: 25196843
31. Data shows that POR*28 allele was not associated with the lipid-lowering effect of atorvastatin. PMID: 24430948
32. results showed that the CYP2C19 and/or P450 oxidoreductase genotypes have an impact on the clearance of clobazam and/or N-desmethylclobazam PMID: 24345815
33. NADPH-cytochrome P450 reductase is regulated by all-trans retinoic acid and by 1,25-dihydroxyvitamin D3 in human acute myeloid leukemia cells. PMID: 24642534
34. The role of Cytochrome P450 reductase is to provide electrons to a redox partner, the interactions with cytochrome P450 2D6 (2D6) were investigated and a possible complex structure is suggested. PMID: 23832577
35. results show that FMO3 E158K and POR A503V polymorphisms are minor sources of nicotine metabolism variation, insufficient to appreciably alter smoking. PMID: 24448396
36. POR*28 allele is an important source of CYP2C9 activity variability and combined with CYP2C9 gene poly-morphisms may explain individual variability in the effect of sulfonylureas. PMID: 24464600
37. Seventeen SNPs of CYP3A5, CYP3A4, COMT, IL-10 and POR were identified. PMID: 24465960
38. Candidate-gene study shows that polymorphisms in PPARalpha and POR might predispose patients being treated with tacrolimus to the development of NODAT after kidney transplantation PMID: 24113216
39. Findings regarding the interaction of NADPH-P450 reductase (NPR) with cellular stress response (CSR) indicated function of NPR in hypoxic response. PMID: 24491563
40. Domain motion is linked closely to the individual steps of the catalytic cycle of cytochrome P450 reductase. PMID: 23911089
41. although POR expression is a potential biomarker of sensitivity to some HAP, identification of other one-electron reductases responsible for HAP activation is needed for their rational clinical development. PMID: 24196959
42. Structural, enzymatic and clinical implications of the NADPH P450 oxidoreductase mutations linked to newly identified disorders in humans, now categorized as POR deficiency[review]. PMID: 23353702
43. POR genetic variants affect CYP2C9 activities. The impact of a POR variant on catalysis varies with the isoform of CYP2C9 and the assay substrate. PMID: 22547083
44. Six novel NADPH-P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations were identified. PMID: 22462747
45. The data suggested that cytochrome P450 reductase plays a major role in reactive oxygen species generation by liver cells under the basal conditions, but a minimal rike during simulated in vitro ischemia-reperfusion injury. PMID: 21973081
46. NADPH cytochrome P450 reductase prevents this translocation and promotes oligomerization of HO-1. PMID: 22545110
47. Studies indicate that electron transfer in cytochrome P450 reductase is conformationally gated. PMID: 21762695
48. Clinical, biochemical, and genetic findings in a large PORD cohort. PMID: 22162478
49. POR*28 C > T polymorphism increases 1-hydroxylation of midazolam after intravenous administration. The polymorphism is associated with increased hepatic, but not intestinal, CYP3A activity in healthy Chinese volunteers. PMID: 22177374
50. These data indicate that the POR*28 SNP is associated with additional increases in early tacrolimus dose-requirements in patients carrying a CYP3A5*1 allele. PMID: 21770725
顯示更多

收起更多
相關(guān)疾病：

Antley-Bixler syndrome, with genital anomalies and disordered steroidogenesis (ABS1); Disordered steroidogenesis due to cytochrome P450 oxidoreductase deficiency (DISPORD)
亞細(xì)胞定位：

Endoplasmic reticulum membrane; Single-pass membrane protein; Cytoplasmic side.
蛋白家族：

NADPH--cytochrome P450 reductase family; Flavodoxin family; Flavoprotein pyridine nucleotide cytochrome reductase family
數(shù)據(jù)庫(kù)鏈接：

HGNC: 9208

OMIM: 124015

KEGG: hsa:5447

STRING: 9606.ENSP00000419970

UniGene: Hs.354056

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human